
Friday morning last week, Novo Nordisk caught the stock market by surprise when the company released its first quarterly report for 2022 half a week before it was scheduled to be published.
In connection with the report, Novo Nordisk upgraded its guidance for the full-year. Novo is now counting on reaching sales growth of 10–14 percent, up from earlier 6–10 percent, and operating growth of 9–13 percent, versus the former estimate of 4–8 percent.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app